FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
CN Energy Group Inc. Stock Slides After Nasdaq Delisting Notice Over Bid Price Rule 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
SAN DIEGO, May 05, 2017 -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, will announce its financial results for the first quarter ending March 31, 2017, before the market opens on Wednesday, May 10, 2017.
The company will hold a conference call and simultaneous webcast at 8:30 AM Eastern Time (5:30 AM Pacific Time) on Wednesday, May 10, 2017 to discuss the company's financial results and provide a business update. Interested parties may access the conference call by dialing (844) 889-7791 (U.S.) or (661) 378-9934 (international) using passcode 10811814. Media and individuals will be in a listen-only mode. Participants are asked to dial in a few minutes prior to the call to register for the event. The conference call will also be webcast live at: http://edge.media-server.com/m/p/8wft6fu5.
A replay of the call will be available through May 17, 11:30 am ET by calling (855) 859-2056 (U.S.) or (404) 537-3406 (international), using passcode 10811814. An archive of the webcast will be available for twelve months following the event on the Obalon Therapeutics website located at http://investor.obalon.com in the “News & Events” section.
About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com.
For Obalon Therapeutics, Inc. Investor Contact: William Plovanic Chief Financial Officer Obalon Therapeutics, Inc. Office: +1 760 607 5103 [email protected] Media: Megan Driscoll EvolveMKD Office Phone: +1 646 517 4220 [email protected]
